Greenblatt D J, Divoll M, Abernethy D R, Locniskar A, Shader R I
Pharmacology. 1983;27 Suppl 2:70-5. doi: 10.1159/000137913.
Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.
目前在美国,有三种苯二氮䓬衍生物被专门用于治疗失眠。氟西泮经生物转化至少产生两种快速出现且快速消除的中间代谢产物,这些代谢产物可能有助于诱导睡眠。最终代谢产物去烷基氟西泮出现缓慢,但半衰期很长,在40至150小时之间。这种代谢产物在多次给药期间会大量蓄积。替马西泮是一种吸收缓慢的药物,半衰期中等,在10 - 20小时范围内。三唑仑的吸收速率中等,但消除迅速(半衰期1.5 - 5小时),基本上不会蓄积。了解苯二氮䓬类催眠药的药代动力学有助于理解它们的临床特性。